PARADISE - MI

Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI

 

Patient Population

Patients with spontaneous AMI, LV systolic dysfunction and/or pulmonary congestion, and 1 out of 8 potential risk factors.

Study Description

The aim of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.

Sponsor

Novartis

Clinical Trials Government Link

Additional information:

Frequently asked questions (FAQ) regarding cardiac clinical research trials. 

To find out if you are eligible for one of our research studies or to receive additional information contact us at: 
(402) 384-2705
 MPCHeartConsultantsResearch@nmhs.org